Uploaded October 2026 | Updated November 2026, 3 hours ago
In this session from the 2026 Rare Neuroimmune Disorders Symposium (RNDS), Haiwen Chen, MD, of Johns Hopkins University, spoke about the biology of MOG antibody disease (MOGAD) [00:00:18]. She used a "your brain is a community" illustration to introduce neurons, oligodendrocytes and other glial cells, and where MOG sits on oligodendrocytes [00:00:59]. She explained what inflammation does to these cells, how children usually recover, and why thinking and learning difficulties such as slower processing speed can persist [00:03:10]. Dr. Chen described why remyelination is often incomplete and why recovering the connections between neurons matters [00:08:01]. She shared her laboratory work comparing neurons grown with and without oligodendrocytes, which found that oligodendrocytes influence how neurons fire and the size of their connection points [00:09:39].
Haiwen Chen, MD, is a pediatric neurologist and neuroscientist who received her medical degree from the University of Maryland. She completed a Pediatrics Residency at The Johns Hopkins Hospital in Baltimore, Maryland, and held a James T. Lubin Fellowship at Johns Hopkins University under the mentorship of Dr. Carlos Pardo. She is interested in understanding how MOGAD affects neurons and oligodendrocytes to cause neurological dysfunction, and is developing an in vitro model system of neurons and glia to study how they are disrupted by MOGAD autoantibodies and the associated inflammatory response.
00:00 Introduction
00:18 Your Brain Is a Community
00:59 The Cells of the Brain
03:10 What Inflammation Does
04:13 Recovery After an Attack
05:54 Thinking and Learning Difficulties
08:01 Why Remyelination Is Incomplete
09:39 The Research Question
10:14 Looking at Brain Cells Up Close
14:22 Measuring Neuron Activity
17:23 Removing Oligodendrocytes
20:11 What It Means and Thanks
In this session from the 2026 Rare Neuroimmune Disorders Symposium (RNDS), Haiwen Chen, MD, of Johns Hopkins University, spoke about the biology of MOG antibody disease (MOGAD) [00:00:18]. She used a "your brain is a community" illustration to introduce neurons, oligodendrocytes and other glial cells, and where MOG sits on oligodendrocytes [00:00:59]. She explained what inflammation does to these cells, how children usually recover, and why thinking and learning difficulties such as slower processing speed can persist [00:03:10]. Dr. Chen described why remyelination is often incomplete and why recovering the connections between neurons matters [00:08:01]. She shared her laboratory work comparing neurons grown with and without oligodendrocytes, which found that oligodendrocytes influence how neurons fire and the size of their connection points [00:09:39].
Haiwen Chen, MD, is a pediatric neurologist and neuroscientist who received her medical degree from the University of Maryland. She completed a Pediatrics Residency at The Johns Hopkins Hospital in Baltimore, Maryland, and held a James T. Lubin Fellowship at Johns Hopkins University under the mentorship of Dr. Carlos Pardo. She is interested in understanding how MOGAD affects neurons and oligodendrocytes to cause neurological dysfunction, and is developing an in vitro model system of neurons and glia to study how they are disrupted by MOGAD autoantibodies and the associated inflammatory response.
00:00 Introduction
00:18 Your Brain Is a Community
00:59 The Cells of the Brain
03:10 What Inflammation Does
04:13 Recovery After an Attack
05:54 Thinking and Learning Difficulties
08:01 Why Remyelination Is Incomplete
09:39 The Research Question
10:14 Looking at Brain Cells Up Close
14:22 Measuring Neuron Activity
17:23 Removing Oligodendrocytes
20:11 What It Means and Thanks
![2026 RNDS | Updates in the CosMOG Trial
In this session from the 2026 Rare Neuroimmune Disorders Symposium (RNDS), Michael Levy, MD, PhD, of Massachusetts General Hospital, gave an update on the CosMOG trial, one of two large phase three trials in MOG antibody disease (MOGAD) [00:00:05]. He explained why preventing attacks matters and what people with a first MOGAD attack can expect [00:01:11]. He described how a MOGAD attack develops and how current medications act on different parts of the immune system [00:02:46]. Dr. Levy explained how the trial drug blocks FcRn so that antibodies are cleared faster, and how it compares with plasma exchange and IVIG [00:05:17]. He covered the trial design for people with relapsing MOGAD, in which everyone is allowed one attack before moving to open-label treatment, and said results may come by next year [00:10:29].
Michael Levy, MD, PhD, is an Associate Neurologist at Massachusetts General Hospital and Research Director of the Division of Neuroimmunology and Neuroinfectious Disease. He completed the MD/PhD program at Baylor College of Medicine and trained at Johns Hopkins, where he started the Neuromyelitis Optica Clinic and Research Laboratory. In 2019, he moved to Massachusetts General Hospital and Harvard Medical School to develop the research program in neuroimmunology.
00:00 Introduction
00:37 About the CosMOG Trial
01:11 Relapse Risk in MOGAD
01:45 Why Preventing Attacks Matters
02:46 How a MOGAD Attack Develops
04:14 How Current Medications Work
05:17 Blocking FcRn
07:53 How the Trial Began
08:53 Other MOGAD Trials
10:29 Trial Design
12:35 The Open-Label Phase and Safety
13:05 Where the Trial Stands 2026 RNDS | Updates in the CosMOG Trial](https://i.ytimg.com/vi/eihyWaVU8Ms/mqdefault.jpg)
![2024 TM Together | Community Q&A
During the 2024 TM Together online event, Krissy Dilger of SRNA was joined by Dr. Paula Barreras of Cedars-Sinai Medical Center and Dr. Hamza Coban of University of Connecticut Health Center. Dr. Barreras and Dr. Coban answered questions from the audience about transverse myelitis (TM), managing relapsing TM, diagnostic tests, and medications [00:07:15]. The doctors also delved into symptom management strategies for neuropathic pain, fatigue, and bladder and bowel dysfunction, emphasizing the importance of personalized treatment plans and ongoing care [00:23:40]. They concluded by highlighting the relevance of new research, particularly in stem cell treatments, and offered encouragement for people living with TM [00:48:05]. Please note that the information shared during this session is for informational purposes only and is not medical advice.
Paula Barreras, MD is a board-certified neurologist with expertise in neuroimmunology. She is an assistant professor of neurology at Cedars-Sinai Medical Center in Los Angeles, CA. Dr. Barreras specializes in immune mediated conditions affecting the brain and spinal cord, including neurosarcoidosis and spinal cord disorders such as neuromyelitis optica, MOG associated disease, transverse myelitis, and their mimics.
Dr. Barreras completed her medical school at the University of the Andes, followed by a postdoctoral research fellowship in neuroimmunology at Johns Hopkins University. She completed her neurology residency and clinical neuroimmunology fellowship also at Johns Hopkins before joining the team at Cedars-Sinai Medical Center. Her research focuses on identifying predictors of final diagnosis after the initial diagnosis of myelopathy, as well as predictors of outcomes in myelitis and neurosarcoidosis.
Hamza Coban, MD is an assistant professor of neurology at University of Connecticut in Farmington, CT. He is a neurologist specializing in neuroimmunology disorders including multiple sclerosis, neuromyelitis optica spectrum disorders (NMOSD), and other rare autoimmune conditions affecting the central nervous system in adults and children. Dr. Coban received his medical degree from Hacettepe University School of Medicine in Ankara, Turkey. After medical school, he did a post-doctoral research fellowship at University of California Los Angeles and University of California San Diego, where he studied neurodegeneration and neuroinflammation in the setting of Alzheimer’s disease and HIV-associated dementia.
He completed his neurology residency at University of Connecticut in Farmington, CT, and served as Chief Resident in his last year of residency. After residency, he completed his fellowship training in neuroimmunology at University of Pennsylvania and Children’s Hospital of Philadelphia. Dr. Coban’s research focuses on the aging and transitional care of neuroinflammatory disorders from pediatrics to adulthood and adulthood to the elderly.
00:00 Introduction and Guest Introductions
01:29 Understanding Relapsing Transverse Myelitis
06:37 Recovery After Transverse Myelitis
12:07 Transverse Myelopathy vs. Transverse Myelitis
16:03 Symptom Management: Neuropathic Pain
22:55 Symptom Management: Fatigue
29:12 Symptom Management: Bowel Dysfunction
35:10 Aging with Transverse Myelitis
41:02 Current Research and Future Directions
53:28 Final Thoughts and Closing Remarks 2024 TM Together | Community Q&A](https://i.ytimg.com/vi/esjW3mJKKIg/mqdefault.jpg)

![2026 RNDS | Rehabilitation in Rare Neuroimmune Disorders
In this session from the 2026 Rare Neuroimmune Disorders Symposium (RNDS), Clarice Sinn, DO, of the University of Kentucky spoke about rehabilitation in rare neuroimmune disorders [00:00:05]. Dr. Sinn focused on electrical stimulation and explained three types: transcutaneous electrical nerve stimulation (TENS) for pain, neuromuscular electrical stimulation (NMES), and functional electrical stimulation (FES) [00:01:13]. She described how NMES helps weakened muscles, the settings that can be adjusted, electrode size and placement, possible side effects, home devices, and how she uses it with children, including those with acute flaccid myelitis [00:04:19]. She covered FES cycling, including its use at the bedside in intensive care units for newly diagnosed children, and research in spinal cord injury [00:10:54]. She also described walking and hand devices that use FES, and noted that insurance coverage varies [00:14:11].
Clarice N. Sinn, DO, MHA, is an associate professor of physical medicine and rehabilitation at the University of Kentucky, where she is medical director and division chief of pediatric rehabilitation medicine at Kentucky Childrens Hospital. A pediatric rehabilitation physician, she earned her medical degree at Ohio University College of Osteopathic Medicine and practiced in Dallas for about eight years, working with Dr. Benjamin Greenberg, before joining the University of Kentucky.
00:00 Introduction by Dr. Pardo
00:48 Welcome and Topic Overview
01:59 Three Types of Electrical Stimulation
04:19 How Neuromuscular Stimulation Works
05:15 Settings and Electrode Placement
07:01 Muscle Fibers and Side Effects
09:02 Research and Home Devices
10:54 Functional Electrical Stimulation
13:18 Stimulation in the Intensive Care Unit
14:11 Walking and Hand Devices
16:54 Closing and Questions 2026 RNDS | Rehabilitation in Rare Neuroimmune Disorders](https://i.ytimg.com/vi/fWYXcJnMZN8/mqdefault.jpg)
![2026 RNDS | Fatigue, Sleep, and Cognition
In this session from the 2026 Rare Neuroimmune Disorders Symposium (RNDS), Elena Grebenciucova, MD, of Northwestern Medicine spoke about fatigue, sleep, and cognition, and how closely the three are tied together. Dr. Grebenciucova explained how poor or interrupted sleep, including untreated obstructive sleep apnea, can affect mood, focus, and memory, and why a person with a rare neuroimmune disorder should not assume every bout of fatigue comes from the disorder itself [00:03:11]. She walked through the types of fatigue (physical, cognitive, emotional, and sleep-related) and common modifiable causes such as caffeine, medications for nerve pain and spasticity, bladder needs at night, chronic pain, and headaches [00:05:28]. She also covered eating patterns, vitamin B12 and vitamin D levels, thyroid function, anxiety and depression, and asking for a dedicated appointment to talk about fatigue [00:15:28]. The talk closed with ways to support thinking skills, including cognitive rehabilitation, aerobic exercise, and sleep supplements to discuss with a physician [00:22:46].
Elena Grebenciucova, MD, completed neurology residency at the University of Chicago in Chicago, Illinois. Dr. Grebenciucova has been interested in autoimmune disorders of the central nervous system, including rare neuroimmune disorders, since medical school. After residency, she completed a neuroimmunology fellowship under the mentorship of Dr. Brenda Banwell and Joseph Berger at the Perelman School of Medicine of the University of Pennsylvania. She is an assistant professor of Neurology (MS/Neuroimmunology) and neurological infections at Northwestern University in Chicago, Illinois, and runs the Transverse Myelitis Center there. Dr. Grebenciucova cares for people living with rare autoimmune conditions, including NMOSD, MOGAD, transverse myelitis, and autoimmune encephalitis.
00:00 Welcome and Introduction
01:51 Starting the Day with Positivity
03:11 How Sleep, Cognition, and Fatigue Connect
05:28 Types and Causes of Fatigue
08:44 Sleep Disorders and Sleep Apnea
10:16 Caffeine and Green Tea
12:04 Medications and Nighttime Bladder Needs
13:32 Chronic Pain and Headaches
15:28 Asking for a Dedicated Fatigue Appointment
16:46 Diet and Daily Habits
19:35 B12, Vitamin D, Thyroid, and Mood
21:25 Ways to Reduce Fatigue
22:46 Cognition and Brain Fog
25:10 Sleep Supplements and Closing 2026 RNDS | Fatigue, Sleep, and Cognition](https://i.ytimg.com/vi/g_QWYDywGkI/mqdefault.jpg)



![Community Meets Clinic 302. Drs. Grace Gombolay and Varun Kannan
The Community Meets Clinic podcast series introduces clinicians and healthcare personnel specializing in rare neuroimmune disorders. In this episode hosted by Krissy Dilger of SRNA, we met Dr. Grace Gombolay and Dr. Varun Kannan, both from Emory University and Childrens Healthcare of Atlanta, designated Centers of Excellence in Rare Neuroimmune Disorders. Dr. Kannan discussed learning alongside families as conditions like MOG antibody disease emerged clinically and his focus on tailoring treatment and supporting clinical trials in a field with few approved therapies [03:37]. Dr. Gombolay outlined her research on biomarker development, a Children’s biobank, advanced MRI collaborations, and participation in the Network of Pediatric MS Centers covering disorders such as MOGAD, NMOSD, optic neuritis, ADEM, and TM [06:36]. They described their multidisciplinary clinic team, highlighted home infusions and telemedicine to reduce burden, and shared personal self-care strategies [10:22]. Dr. Gombolay and Dr. Kannan expressed hope for more trials, remyelination, prevention, and earlier diagnosis aided by AI prompts [20:43].
You can view Dr. Grace Gombolays medical profile here:
https://www.choa.org/doctors/grace-gombolay
You can view Dr. Varun Kannans medical profile here:
https://www.choa.org/doctors/varun-kannan
Grace Gombolay, MD, MSc, FAAN is an Associate Professor at Emory University and Director of the Pediatric Neuroimmunology and Multiple Sclerosis Clinic at Childrens Healthcare of Atlanta. Her research interest involves biomarker development in pediatric neuroinflammatory diseases including autoimmune encephalitis, multiple sclerosis, MOGAD, and NMOSD.
Varun Kannan, MD graduated from Emory University School of Medicine in 2017. He then completed child neurology residency in 2022, followed by pediatric neuroimmunology and multiple sclerosis fellowship at Baylor College of Medicine and Texas Childrens Hospital in 2023. He returned to Emory and Childrens Healthcare of Atlanta in 2023, where he has worked closely with Dr. Grace Gombolay in the neuroimmunology program. He is interested in clinical research regarding severe/relapsing forms of rare neuroimmune disorders including autoimmune encephalitis and MOGAD. He is currently involved in multiple upcoming phase 3 clinical trials exploring new disease modifying treatments for pediatric rare neuroimmune disorders. He is also passionate about medical education and is currently one of the Associate Program Directors for the Emory child neurology residency.
00:00 Welcome
01:56 Dr. Grace Gombolays Journey
03:37 Dr. Varun Kannans Path
05:06 Kannans Research Focus
06:36 Biomarkers and Biobank
10:22 Clinic Team and Care
13:44 Self Care and Balance
16:15 Childrens Healthcare of Atlanta
20:43 Hopeful Future Ahead
24:49 Closing Community Meets Clinic 302. Drs. Grace Gombolay and Varun Kannan](https://i.ytimg.com/vi/hUrRjRHM69s/mqdefault.jpg)
![2026 RNDS | Day Two Kickoff: Quality of Life as a Clinical Outcome
In this session from the 2026 Rare Neuroimmune Disorders Symposium (RNDS), Carlos A. Pardo, MD, of Johns Hopkins University opened day two by explaining that the morning would focus on how people living with rare neuroimmune disorders can recover and keep doing what matters to them, rather than on spinal cord imaging, antibodies, or diagnostic criteria [00:00:35]. He noted that treatments such as plasma exchange, IV methylprednisolone, rituximab, and Ocrevus calm the immune system and help control progression, and that the harder question is how to continue a full, happy life afterward [00:01:24]. Dr. Pardo shared the vitamin P (positivity) and vitamin O he tells the people he treats are an important part of recovery after a diagnosis such as myelitis [00:02:10]. He described quality of life as a personal idea, from dancing with a daughter to watching a childs games, and asked what each person hopes to accomplish through rehabilitation [00:03:27]. He then ran two live audience polls, one on what has helped people feel supported and connected at RNDS and one on how people like to recharge after a full day [00:04:32].
Carlos A. Pardo, MD, is a Professor of Neurology and Pathology in the Division of Neuroimmunology and Neuroinfectious Disorders at Johns Hopkins University School of Medicine in Baltimore, Maryland, and Director of the Johns Hopkins Myelitis and Myelopathy Center. He is the principal investigator of the Neuroimmunopathology Laboratory, a member of the HIV Neurosciences Research Group, and a clinical neurologist at the Multiple Sclerosis and Transverse Myelitis Centers at Johns Hopkins Hospital. His clinical specialization is neuroimmunological and infectious disorders of the nervous system, with particular focus on multiple sclerosis, transverse myelitis, neurosarcoidosis, and neurological complications of autoimmune disorders.
00:00 Good Morning and Welcome Back
00:35 Focus for Day Two
01:24 Treatments and Recovery
02:10 Vitamin P and Vitamin O
03:27 What Quality of Life Means
04:04 Audience Poll on Feeling Supported
05:00 People and Conversation at RNDS
05:39 Audience Poll on Recharging 2026 RNDS | Day Two Kickoff: Quality of Life as a Clinical Outcome](https://i.ytimg.com/vi/hiFZbmD6XAk/mqdefault.jpg)
![201. Steroid Dependence
In this ABCs of MOGAD episode, Steroid Dependence, Krissy Dilger of SRNA was joined by Dr. Eoin Flanagan from the Mayo Clinic in Rochester, MN. They began with a summary of how steroids are used to manage MOG antibody disease, particularly during acute attacks [00:01:25]. Dr. Flanagan described the mechanics of steroids in reducing brain inflammation and the importance of early treatment [00:04:14]. They discussed the concept of steroid dependence and the complications that arise when tapering down the steroid dose [00:05:46]. Dr. Flanagan highlighted alternative treatments to manage steroid dependence and emphasized the importance of working closely with healthcare providers to safely reduce steroid use over time [00:09:42].
Eoin Flanagan, MB, BCh is a Professor of Neurology and Consultant in the departments of Neurology and Laboratory Medicine and Pathology at the Mayo Clinic (Rochester, MN). He completed his medical school training at University College Dublin in Ireland in 2005. He did a medical residency in Ireland and then completed neurology residency, fellowships in neuroimmunology and a masters in clinical and translational science at Mayo Clinic (Rochester, MN). He works in the Autoimmune Neurology and Multiple Sclerosis Clinics and the Neuroimmunology Laboratory at the Mayo Clinic.
His clinical expertise and research are focused on inflammatory myelopathies and their imaging patterns, myelin oligodendrocyte glycoprotein (MOG) antibody associated disorder, neuromyelitis optica spectrum disorders, autoimmune encephalitis, paraneoplastic neurologic disorders, and multiple sclerosis. He is principal investigator on an NIH RO1 grant studying MOG antibody associated disorder.
00:00 Introduction
01:25 Understanding Steroids in MOG Antibody Disease
04:14 Steroid Dosage and Administration
05:46 Steroid Dependence in MOGAD Patients
09:42 Managing Steroid Dependence
14:02 Balancing Inflammation Control and Steroid Risks
17:31 Conclusion 201. Steroid Dependence](https://i.ytimg.com/vi/hkXutCNesok/mqdefault.jpg)